The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2015 ACR/ARHP Annual Meeting: Unknowns Persist Around Sarcoidosis Etiology, Pathogenesis, Treatment

2015 ACR/ARHP Annual Meeting: Unknowns Persist Around Sarcoidosis Etiology, Pathogenesis, Treatment

March 15, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The baseline evaluation in suspected sarcoidosis cases should include a complete history with an emphasis on occupational and environmental exposure, a physical exam, blood tests, chest X-ray, spirometry test, electrocardiogram, an ophthalmologic exam and a purified protein derivative test to screen for tuberculosis.

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Diagnosis, Management of Sarcoidosis in the Heart, Central Nervous System
  • 2015 ACR/ARHP Annual Meeting: RA Pathogenesis and Prevention
  • 2015 ACR/ARHP Annual Meeting: Behçet’s Disease Poses Diagnosis, Treatment Challenges
Explore This Issue
March 2016
Also By This Author
  • Registries & Benchmarking: Implementation of Best Practices Can Work—If Done Right

Pulmonary manifestations can include dyspnea, a cough that’s usually dry, chest pain, wheezing or no symptoms at all. Asthmatic symptoms are common, Dr. Highland said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Sarcoidosis skin involvement can include specific manifestations like maculopapules, subcutaneous nodules, infiltrations of scars and lupus pernio, or non-specific conditions such as erythema nodosum, erythema multiforme and rash, she said.

Manifestations of neurosarcoidosis include CNS masses, aseptic meningitis, encephalopathy, seizures, peripheral neuropathy and myopathy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Cardiac sarcoidosis is a serious form because it “can result in sudden death,” Dr. Highland said. It can take the form of conduction disturbances, ventricular arrhythmia, congestive heart failure, valvular dysfunction, pericarditis and other issues. Survival with cardiac sarcoidosis largely depends on whether a patient has a preserved ejection fraction, she said.

Treatment

It’s important to remember, she said, that “not every patient needs to be treated.”

“If they’re doing fine [and] they’re relatively asymptomatic, remission is likely with only a small minority having relapses,” Dr. Highland said. “Whereas if they have organ dysfunction, they’re more likely to have evidence of persistence or relapses.” And two-thirds of patients have a spontaneous remission “whether we do anything or not.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Clues that should cause clinicians to suspect sarcoidosis include African-American race, female gender, symmetric bilateral hilar adenopathy & an asymptomatic presentation.

Corticosteroids are the first-line treatment choice, followed by immune modulators among those with an inadequate response.2 Infliximab is the only medication that has been proved effective in a double-blind randomized controlled trial, Dr. Highland noted.3

Treatment should probably be started right away, she said, in cases of an active neuromuscular or cardiac disease, hepatosplenic involvement with symptoms, significant hypercalcemia, ophthalmic disease that doesn’t respond to topical steroids and disfiguring dermatologic disease, such as lupus pernio.


Thomas R. Collins is a medical writer based in Florida.

Second Chance

If you missed this session, it’s not too late. Catch it on SessionSelect.

References

  1. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: A significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003 Oct;73(4):720–735.
  2. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: Effects of long term corticosteroid treatment. Thorax. 1996 Mar;51(3):238–247.
  3. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med. 2008 Sep;29(3):533–548.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Systemic Inflammatory Syndromes Tagged With: 2015 ACR/ARHP Annual Meeting, American College of Rheumatology, Diagnosis, Etiology, inflammatory, Pathogenesis, rheumatologist, Sarcoidosis, TreatmentIssue: March 2016

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Diagnosis, Management of Sarcoidosis in the Heart, Central Nervous System
  • 2015 ACR/ARHP Annual Meeting: RA Pathogenesis and Prevention
  • 2015 ACR/ARHP Annual Meeting: Behçet’s Disease Poses Diagnosis, Treatment Challenges
  • 2015 ACR/ARHP Annual Meeting: Better Pain Prevention, Treatment Needed for Older Adults

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.